Targeting the SHP2 phosphatase promotes vascular damage and inhibition of tumor growth

Area of Science:

• Oncology
• Molecular Biology
• Vascular Biology

Background:

• The tyrosine phosphatase SHP2 (PTPN11) is a key oncogene in cancers driven by receptor tyrosine kinases.
• SHP2 activity is crucial for tumor cell proliferation and survival.

Purpose of the Study:

• To investigate the role of SHP2 in regulating tumor vasculature and endothelial cell function.
• To evaluate the anti-tumor efficacy of SHP2 inhibition targeting the tumor endothelium.

Main Methods:

• Genetic and chemical inhibition of SHP2 in mouse models.
• Analysis of tumor vascularity, blood perfusion, and necrosis.
• Assessment of endothelial cell signaling pathways (STAT3, ERK1/2, AKT).

Main Results:

• SHP2 inhibition in endothelial cells suppressed pro-apoptotic STAT3 and activated proliferative ERK1/2 signaling.
• Systemic SHP2 inhibition led to tumor vasculature degeneration, reduced blood perfusion, and increased necrosis.
• SHP2 inhibition's anti-tumor effects were independent of tumor cell targeting or immune modulation.
• Combined inhibition of SHP2 and the Angiopoietin/TIE2/AKT pathway enhanced vascular and anti-tumor effects.

Conclusions:

• SHP2 is essential for endothelial cell survival and tumor vascular remodeling.
• Targeting SHP2 in the tumor endothelium represents a promising anti-cancer strategy.
• Combination therapy with SHP2 and Angiopoietin/TIE2 inhibitors may enhance therapeutic outcomes in relevant human cancers.